Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sigilon Therapeutics Inc (SGTX)

Sigilon Therapeutics Inc (SGTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,931
  • Shares Outstanding, K 32,057
  • Annual Sales, $ 13,374 K
  • Annual Income, $ -54,608 K
  • 60-Month Beta N/A
  • Price/Sales 12.99
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SGTX with:

Options Overview Details

View History
  • Implied Volatility 122.48%
  • Historical Volatility 82.42%
  • IV Percentile 68%
  • IV Rank 82.73%
  • IV High 136.94% on 09/16/21
  • IV Low 53.19% on 07/29/21
  • Put/Call Vol Ratio 2.00
  • Today's Volume 30
  • Volume Avg (30-Day) 97
  • Put/Call OI Ratio 1.43
  • Today's Open Interest 221
  • Open Int (30-Day) 175

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.58
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.69
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +8.17%
on 08/25/21
6.91 -17.66%
on 09/07/21
+0.27 (+4.98%)
since 08/24/21
3-Month
4.33 +31.41%
on 08/20/21
12.01 -52.62%
on 06/28/21
-4.28 (-42.93%)
since 06/24/21

Most Recent Stories

More News
Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today announced that...

SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today reported financial...

SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today reported results...

SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today announced the...

SGTX : 5.69 (-1.90%)
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).

BIIB : 291.71 (-0.51%)
NVO : 100.70 (-1.37%)
AMGN : 213.61 (-0.67%)
CLDX : 55.21 (-1.39%)
PRTA : 75.32 (-4.53%)
SGTX : 5.69 (-1.90%)
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

RHHBY : 46.0100 (-0.88%)
NVO : 100.70 (-1.37%)
ZTS : 204.73 (+0.01%)
SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today reported that...

SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today announced the...

SGTX : 5.69 (-1.90%)
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today announced the...

SGTX : 5.69 (-1.90%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 14.20 (-5.46%)
SANA : 21.65 (-5.91%)
SGTX : 5.69 (-1.90%)
AXLA : 3.07 (unch)
CDAK : 17.20 (-8.75%)
EVLO : 7.25 (-2.95%)
KLDO : 5.54 (-2.12%)
MRNA : 430.14 (-5.38%)
RUBY : 18.60 (-3.63%)
MCRB : 6.94 (-2.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sigilon Therapeutics Inc. is a biotechnology company. It seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform. The company's product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by...

See More

Key Turning Points

3rd Resistance Point 6.02
2nd Resistance Point 5.92
1st Resistance Point 5.80
Last Price 5.69
1st Support Level 5.58
2nd Support Level 5.48
3rd Support Level 5.36

See More

52-Week High 54.32
Fibonacci 61.8% 35.22
Fibonacci 50% 29.32
Fibonacci 38.2% 23.42
Last Price 5.69
52-Week Low 4.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar